You have read all your free articles, to continue reading subscribe to read the rest of this content.
BioInvent International has entered into a cancer immunotherapy research collaboration and license agreement with Pfizer to develop antibodies targeting tumour-associated myeloid cells. Under the terms of the deal, Pfizer will pay BioInvent approximately $10 million in early payments, including aAlready a subscriber Login You have read all your free articles,…
Bonnier Ventures, the venture arm of the Bonnier group, has taken the lead in the USD 1.3 million investment round in Pilloxa. Pilloxa, founded in 2015, has developed a patient centric adherence platform consisting of smart hardware, tailored smartphone apps, data visualization and analytics. TheAlready a subscriber Login You have…
The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808. “FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to bAlready a subscriber Login You…
Diamyd Medical has announced the acquisition of the property in Umeå where production of the recombinant protein GAD65, the active component in the therapeutic diabetes vaccine Diamyd is being established. “The manufacturing facility is a crucial investment for the future and the acquisition gAlready a subscriber Login You have read…
